about
Rare mutations predisposing to familial adenomatous polyposis in Greek FAP patientsEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology GroupIxabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialTumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study.Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer.Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
P50
Q24801277-242DE220-9099-45BF-A26C-4383B4275D45Q27851573-4CC494A1-8EAF-4153-91F7-D7C663714174Q27852057-E5DA8ED1-8AE0-4602-954F-F9C16883486BQ27852062-BF6A1EC7-2741-4B6F-8A2A-843604D38AFFQ28292151-2C3DC54E-AB54-45B8-8C96-3C829A08D248Q28534786-4475953F-237E-4C45-AC94-CE12226D4501Q28554412-D790D77B-6890-47F4-BD0B-8F4714D3C7CAQ28728830-CFE9441C-59FC-40BF-AD1B-3D8175FCD60AQ29417100-7B98912E-CCDA-4B90-8EF5-54CBBCB02748Q30252854-B21743FA-9AEA-4369-828E-F43F6A70FF92Q30986219-3C8E06DA-58DB-492B-B4AE-5447FB6AA1D6Q31043651-BB1E6BA7-B91A-4E1D-B551-916A20405FAEQ31051431-7A73345F-9D7B-4600-A307-17A63D43DF8BQ31805479-13603508-407C-4148-94C9-FEC30FB13E26Q33329211-0BA65EA0-78D3-4D1F-8D07-4DDA0E8D8CE8Q33331651-6DA4E24B-7D49-4D25-87DA-F8DB5903E936Q33332077-9B19DEB2-067E-4E8D-916C-FC196C642BC8Q33334195-6D8F30C9-F694-4563-AB07-A592F2BA3A1EQ33336786-00975C08-CD7B-4875-A3C2-E14A0F2D846DQ33337216-8D265DF4-EE67-48EE-B743-9C5310DCF79AQ33339670-4B3AEFCD-40B3-4931-93C4-D04A6D8EB8B6Q33339836-77398F30-1DF6-40F1-8C7F-F515F6626CA7Q33340565-75EB3DBD-A80A-43C7-92AD-4B192BD7009BQ33341090-6C1E6F7D-740D-423D-932A-0B1D881613CFQ33344019-BCA62F2E-FC04-4E65-83FB-99384DA4EA8EQ33346271-DB3412E6-E1A8-4CBB-95E7-0656F2094B27Q33349006-94F3BBA1-1C83-46F4-9FF4-4083327F1E6AQ33358774-F5F673DA-428E-4155-AF9B-FBBB313BB2A2Q33358845-FF43A3F5-6208-4A49-93CA-10BA9E215DA6Q33359798-3FC2E008-B714-490F-A742-BEDD09DAB064Q33364005-27505AFE-3997-4D12-814B-8F19E865F9F8Q33365837-BDDCE513-7A4E-40E8-93DB-E7A25400B65AQ33366181-CA037426-CEB4-43B6-8D64-01605316AE5EQ33366949-7306FA80-4A61-4458-BFC7-D529D077E793Q33369533-A28FDD4B-F4D3-4269-9B47-9B5DE2A53410Q33371394-E1D6D758-724B-45CD-A88B-2049CC08D707Q33372691-F8058F91-6A52-4C94-B215-A4F4FB81019DQ33372703-4EBEB5F3-994E-45C7-8532-C032D222D95EQ33374794-977EAC3E-0821-4762-8C65-46C1DDB9801FQ33376233-B47F3007-F53A-4128-A593-83558585D794
P50
description
forsker
@nb
researcher
@en
name
G Fountzilas
@ast
G Fountzilas
@nl
George Fountzilas
@da
George Fountzilas
@de
George Fountzilas
@en
George Fountzilas
@fr
George Fountzilas
@nb
George Fountzilas
@nn
George Fountzilas
@sv
type
label
G Fountzilas
@ast
G Fountzilas
@nl
George Fountzilas
@da
George Fountzilas
@de
George Fountzilas
@en
George Fountzilas
@fr
George Fountzilas
@nb
George Fountzilas
@nn
George Fountzilas
@sv
altLabel
G Fountzilas
@en
prefLabel
G Fountzilas
@ast
G Fountzilas
@nl
George Fountzilas
@da
George Fountzilas
@de
George Fountzilas
@en
George Fountzilas
@fr
George Fountzilas
@nb
George Fountzilas
@nn
George Fountzilas
@sv